There are currently 1267 clinical trials in Columbus, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Nationwide Children's Hospital, Ohio State University Comprehensive Cancer Center, Ohio State University and The Ohio State University. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
Recruiting
This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome \[ASyS\]) will be included in the study. Treatment response will be measured by Total improvement score (TIS). Additional information can be found... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: The Ohio State University, Columbus, Ohio
Conditions: Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab together with ustekinumab in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/01/2025
Locations: Ohio Gastroenterology group, Inc., Columbus, Ohio
Conditions: Crohn's Disease
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Recruiting
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
04/01/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio +5 locations
Conditions: Stage I Breast Cancer
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
Recruiting
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
04/01/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio +3 locations
Conditions: HER2-positive Breast Cancer
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Recruiting
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Gender:
FEMALE
Ages:
Between 18 years and 60 years
Trial Updated:
04/01/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio +4 locations
Conditions: Breast Cancer
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Recruiting
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
04/01/2025
Locations: The James Cancer Hospital and Solove Research Institute, Columbus, Ohio
Conditions: Leukemia
ATTUNE® Revision- Complex Primary in Total Knee Arthroplasty Population
Recruiting
Five-year, Prospective, multi-center, non-randomized, non-controlled study of the ATTUNE® Revision total knee prostheses, utilizing the fixed bearing (FB) and rotating platform (RP) tibial component with the posterior stabilizing (PS) femoral component in complex primary total knee arthroplasty.
Gender:
ALL
Ages:
Between 22 years and 80 years
Trial Updated:
04/01/2025
Locations: The Ohio State University Wexner Medical Center, Columbus, Ohio
Conditions: Primary Knee Arthroplasty
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Recruiting
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Riverside Methodist Hospital, Columbus, Ohio
Conditions: Relapsed or Refractory Multiple Myeloma
A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
Recruiting
The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumors. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-expansion). The study will last up to approximately 4 years.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Ohio State University Medical Center, Columbus, Ohio
Conditions: Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Neoplasms, Pancreatic Neoplasm, Colorectal Neoplasms
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
Recruiting
This is a Phase III, double-blind, placebo-controlled, safety and efficacy study of daily SC metreleptin in subjects with Partial Lipodystrophy.
Gender:
ALL
Ages:
12 years and above
Trial Updated:
04/01/2025
Locations: Amryt Research Site, Endocrinology Research Associates Inc, Columbus, Ohio +1 locations
Conditions: Partial Lipodystrophy
CERENOVUS Neurothrombectomy Devices Registry
Recruiting
A post-market registry evaluating the EmboTrap® Revascularization Device, CERENOVUS Large Bore Catheter/ EMBOVAC™ Aspiration Catheter, and CEREGLIDE 71 Intermediate Catheter in acute ischemic stroke patients with confirmed intracranial vessel occlusion.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2025
Locations: Ohio Health, Columbus, Ohio
Conditions: Cerebral Stroke
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
Recruiting
This trial examines colorectal cancer incidence in participants with 1 to 2 non-advanced adenomas randomized to surveillance colonoscopy at 10 years compared to participants randomized to surveillance colonoscopy at 5 and 10 years.
Gender:
ALL
Ages:
Between 50 years and 70 years
Trial Updated:
04/01/2025
Locations: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Conditions: Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum